Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
At what ANC do you hold weekly Taxol for adjuvant therapy of Her2 positive breast cancer?
Answer from: Medical Oncologist at Academic Institution
it depends a little on risk of bleeding and disease, but in general 100k I dose reduce. Hold at 80k.
Comments
Medical Oncologist at Allegheny General Hospital-Western Pennsylvania Hospital
Would hold if ANC less than 1000 Proceed and sup...
Medical Oncologist at Dana-Farber Cancer Institute
In the APT trial, we required an ANC > 800 to dose...
1409
1410
Sign In
or
Register
to read more
5254
Related Questions
What neoadjuvant chemotherapy do you suggest for a rapidly growing triple-negative breast cancer?
Is there any definitive contraindication to use tamoxifen in patients with a brain aneurysm that is being monitored?
How do you differentiate between ERBB2 mutation vs HER2 overexpression testing when selecting patients for tumor-agnostic therapy?
Is 5fx APBI and no endocrine therapy a new standard of care for women over 70 years old with low-risk breast cancer given the interim analysis of the EUROPA trial?
What adjuvant systemic therapy would you recommend for a premenopausal woman with a germline BRCA mutation who initially presented with locally advanced, HR+, HER2-negative (FISH) IDC, but was later found on surgical pathology to have HR+, HER2+ disease (IHC 3+) after neoadjuvant chemotherapy?
What are your top takeaways in Breast Cancer from ASTRO 2024?
How do you approach early-stage breast cancer patients who are asking for ctDNA or tumor marker surveillance (or previously receiving these with another provider) when these are not part of the NCCN or ASCO guidelines?
What factors should be considered when deciding between datopotamab deruxtecan and sacituzumab govitecan for a patient with metastatic breast cancer?
Is there any emerging data demonstrating the utility of performing gene expression assays in TNBC to understand potential chemotherapy sensitivity?
For patients with HbA1c >6 can the INAVO regimen still be utilized if the patient is otherwise fit and has a strategy for ongoing glycemic control?
Would hold if ANC less than 1000 Proceed and sup...
In the APT trial, we required an ANC > 800 to dose...